Physician profile
Jane P Steiger
NPI 1598979205
$955.97
in general payments reported to CMS, 2019-2025
12 companies · $74.35 in 2025
The $74.35 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $92.97 · 2021: $156 · 2022: $377 · 2023: $110 · 2024: $38.03 · 2025: $74.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $222.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $272.95 | 2019-2023 | Gardasil 9, Vaxneuvance, Vaqta |
| Glaxosmithkline, LLC. | $206.04 | 2019-2025 | Bexsero |
| Cranial Technologies, INC | $114.36 | 2019-2025 | Doc Band |
| Pfizer INC. | $114.32 | 2020-2023 | |
| Sanofi Pasteur INC. | $109.63 | 2019-2024 | |
| Phadia US INC. | $35.72 | 2021-2022 | |
| Qiagen, LLC | $23.59 | 2020 | |
| Sanofi-Aventis U.S. LLC | $22.30 | 2025 | |
| Seqirus USA INC | $18.96 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.42 | 2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $12.81 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $10.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Steiger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.